InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
3
T+90 hit rate
22%
T+90 mean return
-12.7%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Houston John G, Chairman & CEO. Officer active across 1 company, notably Arvinas, INC.. Aggregated, 16 reports have been recorded. Split: 0 buy · 3 sells. Total volume traded: €726k. Activity tracked since 9 June 2021. The latest transaction was disclosed on 24 February 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations16 total
26,184 shares@ US$16.7513.3% of flowCommon StockSEC:0001655759-25-000048:0
5,154 shares@ US$16.552.6% of flowCommon StockSEC:0001655759-25-000048:1
152,000 shares0Common StockSEC:0001655759-25-000019:0
124,450 shares0Common StockSEC:0001655759-24-000028:0
5,196 shares@ US$47.057.2% of flowCommon StockSEC:0001655759-24-000028:1
17,510 sharesCommon StockSEC:0001655759-23-000025:0
61,975 shares0Common StockSEC:0001655759-23-000018:0
17,511 sharesCommon StockSEC:0001209191-22-016529:0
40,000 shares@ US$16.000.073% mcap22.9% of flowCommon StockSEC:0000899243-21-042947:0
40,000 shares@ US$16.0017.6% of flowCommon StockSEC:0000899243-21-042947
2,228 shares@ US$16.000.0039% mcap1.2% of flowCommon StockSEC:0001209191-21-055079:0
2,228 shares@ US$16.001.0% of flowCommon StockSEC:0001209191-21-055079
45,922 shares@ US$16.000.081% mcap25.5% of flowCommon StockSEC:0001209191-21-049804:0
45,922 shares@ US$16.0019.6% of flowCommon StockSEC:0001209191-21-049804
700 shares@ US$16.000.0012% mcap0.4% of flowCommon StockSEC:0000899243-21-023375:0
700 shares@ US$16.000.3% of flowCommon StockSEC:0000899243-21-023375
16 of 16 declarations
About Houston John G
John G. Houston is the President and CEO of ARVINAS, INC. He is responsible for the strategic direction of the company and the management of daily operations. With extensive experience in the industry, Houston focuses on innovation and the development of therapeutic solutions to improve patient lives.
